Behind the Paper

The real stories behind the latest research papers, from conception to publication, the highs and the lows

The REZPEG Story

Impaired interleukin-2 production and regulatory T cell (Treg) dysfunction is implicated in multiple autoimmune diseases. Here, in two phase 1b trials, we show that rezpegaldesleukin, a Treg-selective pegylated IL-2, is safe and improves symptoms in patients with atopic dermatitis or psoriasis.
Go to the profile of Jonathan Zalevsky
Nov 01, 2024